Seladelpar, a PPAR-delta Agonist, Improves Inflammatory Lipid Mediators in the Serum Metabolome in Patients

Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease characterized by chronic inflammation and cholestasis due to damaged intrahepatic bile ducts. Seladelpar is a potent, selective peroxisome proliferator-activated receptor-delta (PPAR ) agonist being developed for PBC. In recent phase 2 and phase 3 studies in patients with PBC, seladelpar significantly improved biochemical markers associated with cholestasis, liver injury and risk for disease progression, and it also reduced lipids associated with cardiovascular risk.

View this poster to learn how CymaBay Therapeutics used Metabolon’s Global Discovery Panel to perform an untargeted serum metabolomic study to further investigate mechanisms underlying the beneficial effects of seladelpar.